Home › Research › Treatments
N-terminal-targeted anti-amyloid monoclonal antibodies illuminate the therapy for Alzheimer’s disease: a systematic review and comprehensive meta-analysis
Qiu Y, Liu M, Zhan J, Liu L, Zheng J, Wu D, Wu G, Cai Y et al.. medRxiv, 2023-11-22
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Summary Background Recent clinical trials of anti-amyloid-beta (Aβ) monoclonal antibodies (mAbs) have demonstrated that the removal of Aβ in symptomatic patients can slow down the progression of Alzheimer’s disease (AD) and reinforce the “amyloid cascade” hypothesis. The analysis revealed that eight monoclonal antibodies (aducanumab, lecanemab, donanemab, bapineuzumab, gantenerumab, crenezumab, solanezumab, and ponezumab) demonstrated statistical improvements in cognitive outcomes. Specifically, the ADAS-cog [(total mAbs: SMD: -0.08, 95% CI: -0.11 to -0.04); (N-terminal-targeted mAbs: SMD: -0.08, 95% CI: -0.13 to -0.03)], CDR-SB [(total mAbs: SMD: -0.06, 95% CI: -0.12 to -0.00); (N-terminal-targeted mAbs: SMD: -0.08, 95% CI: -0.16 to -0.01)], and MMSE [(total mAbs: SMD: 0.06, 95% CI: 0.02 to 0.10); (N-terminal-targeted mAbs: SMD: 0.05, 95% CI: -0.00 to 0.10)] demonstrated significant improvement. In addition, the meta-analyses indicated that mAbs also had a statistically significant impact on reducing amyloid PET [(total mAbs: SMD: -1.13, 95% CI: -1.66 to -0.61); (N-terminal-targeted mAbs: SMD: -1.64, 95% CI: -2.27 to -1.02)], accelerating ventricle enlargement [(total mAbs: SMD: 0.22, 95% CI: 0.06 to 0.38); (N-terminal-targeted mAbs: SMD: 0.44, 95% CI: 0.30 to 0.57)], and causing whole-brain atrophy [(total mAbs: SMD: -0.14, 95% CI: -0.26 to -0.03); (N-terminal-targeted mAbs: SMD: -0.24, 95% CI: -0.41 to -0.07)], while increased the risk ARIA-E (total mAbs: RR: 9.79, 95% CI 7.83 to 12.26); (N-terminal-targeted mAbs: RR: 10.79, 95% CI: 8.61 to 13.52)] and ARIA-H [(total mAbs: RR: 1.28, 95% CI 0.98 to 1.67); (N-terminal-targeted mAbs: RR: 1.94, 95% CI: 1.64 to 2.29)]. However, no significant hippocampal volume atrophy was observed [(total mAbs: SMD: 0.00, 95% CI: -0.07 to 0.07); (N-terminal-targeted mAbs: SMD: -0.03, 95% CI: -0.13 to 0.07)]. It should be noted that all above effects were more significant in AD patients treated with N-terminal-targeted mAbs, as observed in subgroup analyses. Additionally, we observed a negative association between ventricular enlargement and Aβ clearance (Pearson’s r: -0.76), especially with the administration of N-terminal-targeted mAbs (Pearson’s r: -0.79), indicating a stronger effect on Aβ clearance. Interpretation The administration of mAbs that specifically target the N-terminus of Aβ showed promising results in reducing Aβ burden and ameliorating cognitive decline. In future anti-Aβ mAb development, our systematic rev
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Qiu, Y., Liu, M., Zhan, J., Liu, L., Zheng, J., Wu, D., et al. (2023). N-terminal-targeted anti-amyloid monoclonal antibodies illuminate the therapy for Alzheimer’s disease: a systematic review and comprehensive meta-analysis. medRxiv. https://doi.org/10.1101/2023.11.20.23298794
Vancouver
Qiu Y, Liu M, Zhan J, Liu L, Zheng J, Wu D, et al. N-terminal-targeted anti-amyloid monoclonal antibodies illuminate the therapy for Alzheimer’s disease: a systematic review and comprehensive meta-analysis. medRxiv. 2023. doi:10.1101/2023.11.20.23298794.
BibTeX
@article{qiu2023-1baddf3f,
author = {Qiu, Y. and Liu, M. and Zhan, J. and Liu, L. and Zheng, J. and Wu, D. and Wu, G. and Cai, Y. and others},
title = {{N-terminal-targeted anti-amyloid monoclonal antibodies illuminate the therapy for Alzheimer’s disease: a systematic review and comprehensive meta-analysis}},
journal = {medRxiv},
year = {2023},
doi = {10.1101/2023.11.20.23298794},
url = {https://doi.org/10.1101/2023.11.20.23298794}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Summary Background Recent clinical trials of anti-amyloid-beta (Aβ) monoclonal antibodies (mAbs) have demonstrated that the removal of Aβ in symptomatic patients can slow down the progression of Alzheimer’s disease (AD) and reinforce the “amyloid cascade” hypothesis.
- The analysis revealed that eight monoclonal antibodies (aducanumab, lecanemab, donanemab, bapineuzumab, gantenerumab, crenezumab, solanezumab, and ponezumab) demonstrated statistical improvements in cognitive outcomes.
- Specifically, the ADAS-cog [(total mAbs: SMD: -0.08, 95% CI: -0.11 to -0.04); (N-terminal-targeted mAbs: SMD: -0.08, 95% CI: -0.13 to -0.03)], CDR-SB [(total mAbs: SMD: -0.06, 95% CI: -0.12 to -0.00); (N-terminal-targeted mAbs: SMD: -0.08, 95% CI: -0.16 to -0.01)], and MMSE [(total mAbs: SMD: 0.06, 95% CI: 0.02 to 0.10); (N-terminal-targeted mAbs: SMD: 0.05, 95% CI: -0.00 to 0.10)] demonstrated significant improvement.
- In addition, the meta-analyses indicated that mAbs also had a statistically significant impact on reducing amyloid PET [(total mAbs: SMD: -1.13, 95% CI: -1.66 to -0.61); (N-terminal-targeted mAbs: SMD: -1.64, 95% CI: -2.27 to -1.02)], accelerating ventricle enlargement [(total mAbs: SMD: 0.22, 95% CI: 0.06 to 0.38); (N-terminal-targeted mAbs: SMD: 0.44, 95% CI: 0.30 to 0.57)], and causing whole-brain atrophy [(total mAbs: SMD: -0.14, 95% CI: -0.26 to -0.03); (N-terminal-targeted mAbs: SMD: -0.24, 95% CI: -0.41 to -0.07)], while increased the risk ARIA-E (total mAbs: RR: 9.79, 95% CI 7.83 to 12.26); (N-terminal-targeted mAbs: RR: 10.79, 95% CI: 8.61 to 13.52)] and ARIA-H [(total mAbs: RR: 1.28, 95% CI 0.98 to 1.67); (N-terminal-targeted mAbs: RR: 1.94, 95% CI: 1.64 to 2.29)].
- However, no significant hippocampal volume atrophy was observed [(total mAbs: SMD: 0.00, 95% CI: -0.07 to 0.07); (N-terminal-targeted mAbs: SMD: -0.03, 95% CI: -0.13 to 0.07)].
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designsystematic review
- Participants34
- Effect sizeRR: 9.79; RR: 10.79; RR: 1.28
- Evidence strengthHigh
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 55 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 34 of the 62 points we could judge it on, which is 55 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 34 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 34 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 34 of the 62 points we could judge it on is 55 out of 100. |
| Total | 55 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “comprehensive-meta-analysis”
2 studies in the library carry the topic tag “comprehensive-meta-analysis”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.